Regatta Capital Group LLC cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 25.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,951 shares of the company’s stock after selling 1,733 shares during the period. Regatta Capital Group LLC’s holdings in Johnson & Johnson were worth $716,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently made changes to their positions in the company. IFS Advisors LLC grew its holdings in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares in the last quarter. Highline Wealth Partners LLC purchased a new stake in Johnson & Johnson during the 3rd quarter valued at about $31,000. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson in the 3rd quarter worth approximately $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after purchasing an additional 91 shares during the last quarter. Finally, Activest Wealth Management purchased a new stake in shares of Johnson & Johnson in the third quarter valued at approximately $40,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $151.27 on Thursday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The firm has a 50 day moving average of $147.76 and a two-hundred day moving average of $156.13. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $364.20 billion, a PE ratio of 22.75, a P/E/G ratio of 2.45 and a beta of 0.51.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.28%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.
Insider Activity
In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.16% of the company’s stock.
Wall Street Analysts Forecast Growth
JNJ has been the topic of a number of recent research reports. Leerink Partners dropped their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Bank of America dropped their price objective on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a report on Thursday, January 23rd. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Morgan Stanley cut their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $170.44.
Check Out Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
- Five stocks we like better than Johnson & Johnson
- What is the Euro STOXX 50 Index?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- How to Invest in Blue Chip Stocks
- 3 Steel Stocks Soaring After Tariff Announcements
- Retail Stocks Investing, Explained
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.